A detailed history of Northern Trust Corp transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Northern Trust Corp holds 1,228,442 shares of ABUS stock, worth $3.92 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,228,442
Previous 1,051,325 16.85%
Holding current value
$3.92 Million
Previous $3.25 Million 45.6%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$3.12 - $4.56 $552,605 - $807,653
177,117 Added 16.85%
1,228,442 $4.73 Million
Q2 2024

Aug 14, 2024

SELL
$2.52 - $3.63 $13,303 - $19,162
-5,279 Reduced 0.5%
1,051,325 $3.25 Million
Q1 2024

May 14, 2024

SELL
$2.26 - $2.92 $26,254 - $33,921
-11,617 Reduced 1.09%
1,056,604 $2.73 Million
Q4 2023

Feb 13, 2024

BUY
$1.69 - $2.54 $4,814 - $7,236
2,849 Added 0.27%
1,068,221 $2.67 Million
Q3 2023

Nov 13, 2023

BUY
$1.9 - $2.27 $41,630 - $49,737
21,911 Added 2.1%
1,065,372 $2.16 Million
Q2 2023

Aug 11, 2023

BUY
$2.24 - $3.06 $209,599 - $286,327
93,571 Added 9.85%
1,043,461 $2.4 Million
Q1 2023

May 15, 2023

BUY
$2.23 - $3.1 $69,462 - $96,561
31,149 Added 3.39%
949,890 $2.88 Million
Q4 2022

Feb 13, 2023

BUY
$1.91 - $2.85 $34,750 - $51,852
18,194 Added 2.02%
918,741 $2.14 Million
Q3 2022

Nov 14, 2022

BUY
$1.88 - $2.88 $6,721 - $10,296
3,575 Added 0.4%
900,547 $1.72 Million
Q2 2022

Aug 12, 2022

BUY
$1.98 - $3.17 $243,011 - $389,063
122,733 Added 15.85%
896,972 $2.43 Million
Q1 2022

May 13, 2022

BUY
$2.42 - $3.98 $96,245 - $158,288
39,771 Added 5.41%
774,239 $2.31 Million
Q4 2021

Feb 08, 2022

BUY
$3.11 - $4.61 $105,628 - $156,574
33,964 Added 4.85%
734,468 $2.86 Million
Q3 2021

Nov 15, 2021

SELL
$2.65 - $4.62 $49,435 - $86,186
-18,655 Reduced 2.59%
700,504 $3.01 Million
Q2 2021

Aug 13, 2021

BUY
$2.5 - $3.51 $1.47 Million - $2.06 Million
586,456 Added 441.93%
719,159 $2.18 Million
Q1 2021

May 12, 2021

BUY
$3.14 - $4.84 $58,090 - $89,540
18,500 Added 16.2%
132,703 $442,000
Q4 2020

Feb 11, 2021

SELL
$2.76 - $4.97 $15,124 - $27,235
-5,480 Reduced 4.58%
114,203 $405,000
Q3 2020

Nov 16, 2020

BUY
$1.75 - $6.2 $29,568 - $104,755
16,896 Added 16.44%
119,683 $375,000
Q2 2020

Aug 14, 2020

BUY
$0.91 - $2.36 $93,536 - $242,577
102,787 New
102,787 $188,000
Q3 2019

Nov 13, 2019

SELL
$1.34 - $2.4 $392,724 - $703,387
-293,078 Closed
0 $0
Q2 2019

Aug 13, 2019

SELL
$1.46 - $4.44 $30,195 - $91,828
-20,682 Reduced 6.59%
293,078 $610,000
Q1 2019

May 13, 2019

BUY
$3.41 - $4.57 $9,009 - $12,073
2,642 Added 0.85%
313,760 $1.12 Million
Q4 2018

Feb 12, 2019

SELL
$3.5 - $9.66 $72,065 - $198,899
-20,590 Reduced 6.21%
311,118 $1.19 Million
Q3 2018

Nov 14, 2018

BUY
$7.85 - $12.35 $277,042 - $435,856
35,292 Added 11.91%
331,708 $3.14 Million
Q2 2018

Aug 14, 2018

BUY
$5.0 - $7.35 $1.48 Million - $2.18 Million
296,416 New
296,416 $2.16 Million

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $478M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.